文献速递前列腺癌

M1a/M1b期前列腺癌确诊时行或不行根治性前列腺切除术的治疗

Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-01-03

单中心回顾性分析2007至2014年47例转移性前列腺癌患者,31例(66%)接受根治性前列腺切除术(RP)联合或不联合辅助治疗,16例(34%)仅接受雄激素剥夺治疗(ADT)。中位随访38.8个月,5年癌症特异性死亡无生存率全队列为57.9%,手术组62% vs ADT组46%(P=0.3)。作者认为局部手术治疗可行,但短期未见生存获益,需进一步前瞻性研究。

要点

  • 47例转移性前列腺癌中31例(66%)行RP,16例(34%)仅ADT,5年CSM无生存率手术组62% vs ADT组46%(P=0.3)。
  • RP组30天总并发症率29%(n=9),30天再入院率9.7%,中位住院3天。
  • 随访期间所有治疗患者均恢复控尿,但短期未见手术较ADT的生存获益。

核心结论

  • 作者认为转移性前列腺癌原发灶局部手术治疗可行,但短期未观察到手术较仅ADT的生存获益,需进一步前瞻性研究探索M1a/M1b期前列腺癌的治疗。

研究设计与样本

  • 单中心回顾性研究,纳入2007至2014年在梅奥诊所(Mayo Clinic, Rochester, MN)由两位泌尿外科医生(RJK和EK)治疗的47例转移性前列腺癌患者。
  • 31例(66%)接受根治性前列腺切除术(RP)联合或不联合辅助治疗,16例(34%)仅接受雄激素剥夺治疗(ADT);手术患者由单一外科医生(RJK)治疗。

主要发现

  • 诊断时中位年龄61岁,中位随访38.8个月期间记录12例死亡。
  • 5年癌症特异性死亡(CSM)无生存率全队列为57.9%,手术组为62% vs ADT组为46%(P=0.3)。
  • RP组中位住院时间3天,30天再入院率9.7%,30天总并发症率29%(n=9)。
  • RP组具体并发症:淋巴囊肿2例(6.5%)、伤口感染2例(6.5%)、肠梗阻2例(6.5%)、血肿2例(6.5%)、吻合口漏1例(3.2%)。
  • 术后90天内,2例(6.5%)需要1至2片支持垫,5例(16.1%)需要3片或以上垫;随访期间所有治疗患者均达到控尿。

局限性

  • 原文在结论中写明需进一步前瞻性研究来探索M1a/M1b期前列腺癌患者的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the study was to evaluate survival and perioperative outcomes of metastatic prostate cancer (mPCa) patients treated with surgery or androgen deprivation treatment (ADT) only. METHODS: We retrospectively selected 47 metastatic PCa patients treated at a single center (Mayo Clinic, Rochester, MN) by two urologists (RJK and EK) between 2007 and 2014. Overall, 31 (66%) underwent radical prostatectomy (RP) with or without adjuvant therapies and 16 (34%) underwent ADT only. Surgical patients were treated by a single surgeon (RJK). Complications and functional outcomes were recorded for surgery group. Cancer-specific mortality (CSM) was analyzed by Kaplan-Meier estimation. Univariable Cox regression analyses were used to test the risk factors associated with CSM in mPCa patients treated with RP. RESULTS: Median age at diagnosis was 61 years. During median follow-up 38.8 months, 12 deaths were recorded. At 5 years, the overall CSM-free survival rate of the whole cohort was 57.9%. When patients were stratified according to the treatment, CSM-free survival rate at 5 years was 62% and 46% for patients who underwent surgery and ADT, respectively (P=0.3). Median length of stay was 3 days, with a 30 days readmission rate of 9.7%. The 30-day all complication rate was 29% (n=9). Specifically, we recorded: 2 lymphoceles (6.5%), 2 wound infection (6.5%), 2 ileus (6.5%), 2 hematoma (6.5%) and 1 anastomosis leak (3.2%). Within 90 days after surgery, 2 (6.5%) and 5 (16.1%) patients needed 1-2 supportive and 3 or more pads, respectively. However, continence was achieved by all treated patients during the follow-up period. CONCLUSIONS: We demonstrated the feasibility of local surgical treatment of primary tumor in mPCa patients. However, in the short term, no survival benefits have been observed for patients treated with surgery when compared with patients treated with ADT only. Further prospective studies are warranted to explore the treatment of M1a/M1b prostate cancer patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Moschini M, Morlacco A, Kwon E, et al. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis. 2017. PMID: 28045114. doi:10.1038/pcan.2016.63

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。